Psyence Biomedical (PBM) Competitors $0.05 0.00 (-8.20%) (As of 02:15 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends PBM vs. TSBX, CDT, INDP, IPA, PHXM, KPRX, MBIO, SNTI, IMNN, and TRIBShould you be buying Psyence Biomedical stock or one of its competitors? The main competitors of Psyence Biomedical include Turnstone Biologics (TSBX), Conduit Pharmaceuticals (CDT), Indaptus Therapeutics (INDP), ImmunoPrecise Antibodies (IPA), PHAXIAM Therapeutics (PHXM), Kiora Pharmaceuticals (KPRX), Mustang Bio (MBIO), Senti Biosciences (SNTI), Imunon (IMNN), and Trinity Biotech (TRIB). These companies are all part of the "pharmaceutical products" industry. Psyence Biomedical vs. Turnstone Biologics Conduit Pharmaceuticals Indaptus Therapeutics ImmunoPrecise Antibodies PHAXIAM Therapeutics Kiora Pharmaceuticals Mustang Bio Senti Biosciences Imunon Trinity Biotech Turnstone Biologics (NASDAQ:TSBX) and Psyence Biomedical (NASDAQ:PBM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation, community ranking and profitability. Does the media prefer TSBX or PBM? In the previous week, Turnstone Biologics had 2 more articles in the media than Psyence Biomedical. MarketBeat recorded 5 mentions for Turnstone Biologics and 3 mentions for Psyence Biomedical. Psyence Biomedical's average media sentiment score of 0.73 beat Turnstone Biologics' score of -0.40 indicating that Psyence Biomedical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Turnstone Biologics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Psyence Biomedical 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend TSBX or PBM? Turnstone Biologics presently has a consensus price target of $2.13, indicating a potential upside of 342.71%. Given Turnstone Biologics' stronger consensus rating and higher possible upside, equities analysts clearly believe Turnstone Biologics is more favorable than Psyence Biomedical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Turnstone Biologics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Psyence Biomedical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in TSBX or PBM? Turnstone Biologics received 4 more outperform votes than Psyence Biomedical when rated by MarketBeat users. CompanyUnderperformOutperformTurnstone BiologicsOutperform Votes450.00% Underperform Votes450.00% Psyence BiomedicalN/AN/A Which has preferable valuation and earnings, TSBX or PBM? Psyence Biomedical has lower revenue, but higher earnings than Turnstone Biologics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTurnstone Biologics$19.31M0.57-$55.20M-$3.24-0.15Psyence BiomedicalN/AN/A-$51.16MN/AN/A Is TSBX or PBM more profitable? Psyence Biomedical's return on equity of 0.00% beat Turnstone Biologics' return on equity.Company Net Margins Return on Equity Return on Assets Turnstone BiologicsN/A -105.99% -87.27% Psyence Biomedical N/A N/A N/A Which has more risk and volatility, TSBX or PBM? Turnstone Biologics has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500. Comparatively, Psyence Biomedical has a beta of -0.43, suggesting that its share price is 143% less volatile than the S&P 500. Do insiders and institutionals have more ownership in TSBX or PBM? 52.5% of Turnstone Biologics shares are owned by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are owned by institutional investors. 32.1% of Turnstone Biologics shares are owned by company insiders. Comparatively, 3.6% of Psyence Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryTurnstone Biologics beats Psyence Biomedical on 8 of the 13 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Psyence Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for PBM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBM vs. The Competition Export to ExcelMetricPsyence BiomedicalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.91M$6.53B$5.10B$8.84BDividend YieldN/A8.11%5.04%4.07%P/E RatioN/A5.5095.1214.22Price / SalesN/A375.021,217.3088.42Price / CashN/A52.5939.4936.27Price / Book-0.0610.276.976.37Net Income-$51.16M$153.22M$118.73M$225.56M7 Day PerformanceN/A-1.19%-1.22%-0.02%1 Month PerformanceN/A-6.71%-3.07%2.04%1 Year PerformanceN/A32.39%32.52%28.00% Psyence Biomedical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBMPsyence BiomedicalN/A$0.05-8.2%N/AN/A$2.91MN/A0.00N/ANews CoverageTSBXTurnstone Biologics3.2023 of 5 stars$0.48+4.4%$2.13+342.7%-84.8%$11.10M$19.31M0.0082CDTConduit PharmaceuticalsN/A$0.11+22.0%N/A-92.8%$10.81MN/A0.003News CoverageGap UpHigh Trading VolumeINDPIndaptus Therapeutics2.7304 of 5 stars$1.05-1.4%$8.50+713.4%-48.7%$10.66MN/A0.006IPAImmunoPrecise Antibodies2.0348 of 5 stars$0.37-4.2%$6.00+1,523.8%-72.2%$10.65M$18.16M0.0080PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049KPRXKiora Pharmaceuticals2.9909 of 5 stars$3.38-1.2%$10.00+195.9%-32.4%$10.14MN/A0.0010MBIOMustang Bio1.9526 of 5 stars$0.21+0.3%$2.00+853.7%-87.6%$10.02MN/A-0.13100SNTISenti Biosciences1.0644 of 5 stars$2.16+1.9%N/A-42.1%$9.91M$2.56M-0.144News CoverageIMNNImunon2.7245 of 5 stars$0.68-0.7%$12.00+1,667.3%-26.5%$9.85M$500,000.00-0.3633Gap DownTRIBTrinity Biotech1.8381 of 5 stars$1.28-1.5%N/A-33.5%$9.75M$56.83M-0.58480 Related Companies and Tools Related Companies Turnstone Biologics Alternatives Conduit Pharmaceuticals Alternatives Indaptus Therapeutics Alternatives ImmunoPrecise Antibodies Alternatives PHAXIAM Therapeutics Alternatives Kiora Pharmaceuticals Alternatives Mustang Bio Alternatives Senti Biosciences Alternatives Imunon Alternatives Trinity Biotech Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PBM) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psyence Biomedical Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Psyence Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
